Tradingview
Published November 17, 2026
ENSC: A 2027 CRPS Phase II leads a psychedelic pain pipeline targeting dosing in Q1 2028
Read the full story at Tradingview
A $77 million PIPE is funding a planned 2027 Phase II trial of psilocybin-based therapy for CRPS, with interim data expected in H2 2027.
Surfaced by this Google Alert
- Psychedelics